TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib

被引：0
|
作者：
Kito, Yosuke [1 ]
Hamauchi, Satoshi [1 ]
Yamazaki, Kentaro [1 ]
Komori, Azusa [2 ]
Masuishi, Toshiki [2 ]
Taniguchi, Hiroya [2 ]
Mori, Keita [3 ]
Muro, Kei [2 ]
Yasui, Hirofumi [1 ]
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Nagaizumi, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Shizuoka Canc Ctr, Clin Res Ctr, Nagaizumi, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1 - 8 - 3
引用
收藏
页数：1
相关论文
共 50 条
  • [31] TAS-102 in refractory colorectal cancer: caution is needed
    Sobrero, Alberto
    LANCET ONCOLOGY, 2012, 13 (10): : 959 - 961
  • [32] Both regorafenib and TAS-102 give metastatic colorectal cancer patients survival benefit with different toxicity profile
    Sugimoto, Naotoshi
    Yoshinami, Tetsuhiro
    Yamamoto, Sachiko
    Yagi, Toshinari
    Imamura, Fumio
    ANNALS OF ONCOLOGY, 2015, 26 : 100 - 100
  • [33] Retrospective analysis of TAS-102 for metastatic colorectal cancer
    Aoki, M.
    Shimamoto, F.
    Ikegami, T.
    Yamaguchi, T.
    Terazawa, T.
    Kii, T.
    Goto, M.
    Higuchi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] TAS-102 plus bevacizumab in metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    LANCET ONCOLOGY, 2020, 21 (05): : E226 - E226
  • [35] TAS-102 followed by regorafenib or the reverse sequence in advanced colorectal cancer
    Nakatani, Y.
    Ueda, S.
    Tsuboguchi, Y.
    Yoshii, Y.
    Akiyoshi, K.
    Tsuya, A.
    Okazaki, S.
    Tokunaga, S.
    Daga, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] A novel antimetabolite: TAS-102 for metastatic colorectal cancer
    Miyamoto, Yuji
    Lenz, Heinz-Josef
    Baba, Hideo
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 355 - 365
  • [37] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [38] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    BMC Gastroenterology, 21
  • [39] Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).
    Nishina, Tomohiro
    Yoshino, Takayuki
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Baba, Hideo
    Tsuji, Akihito
    Yamaguchi, Kensei
    Muro, Kei
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [40] A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)
    Yamazaki, K.
    Kuboki, Y.
    Nishina, T.
    Shinozaki, E.
    Shitara, K.
    Okamoto, W.
    Kajiwara, T.
    Matsumoto, T.
    Tsushima, T.
    Mochizuki, N.
    Fukutani, M.
    Nakamoto, M.
    Hasegawa, Y.
    Sugama, A.
    Nomura, S.
    Sato, A.
    Ohtsu, A.
    Yoshino, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S368 - S369
12345